LASN-01 is under clinical development by Lassen Therapeutics 1 and currently in Phase II for Graves’ Ophthalmopathy. According to GlobalData, Phase II drugs for Graves’ Ophthalmopathy have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LASN-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LASN-01 overview

LASN-01 is under development for the treatment of thyroid eye disease(TED) or Graves ophthalmopathy, idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung disease (PF-ILD), triple negative breast cancer and skin fibrosis (systemic sclerosis). It acts by targeting interleukin 11 receptor alpha(IL-11R). It is administered through intravenous route.

Lassen Therapeutics 1 overview

Lassen Therapeutics 1 (Lassen Therapeutics) is a biotechnology company developing antibodies for fibrosis, rare diseases, and oncology indications. The company is investigating its lead candidate LASN-01, a monoclonal antibody to treat chronic fibrotic, inflammatory diseases and multiple tumor types. Its product candidate targets and blocks interleukin 11 receptor alpha (IL-11R) that acts as a central mediator of fibrosis. The company works in partnership with Cedars-Sinai to develop its products. Lassen Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of LASN-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.